St Vincent adds BRCA2 to testing service
This article was originally published in Clinica
St Vincent Medical Center's Los Angeles Oncologic Institute has extended its breast cancer gene diagnosis service to include the recently discovered breast and ovarian cancer gene, BRCA2. The unit, headed by Dr Ellen Knell, has been testing for BRCA1 mutations for six months. The service is available to women with a family history of breast and ovarian cancer and at least one living affected relative, and Ashkenazi Jewish women, who are at very high risk of inherited breast cancer. Affected relatives are needed because not all mutations change the function of the gene.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.